The safety results from the EoE KIDS study were consistent with the known safety profile of Dupixent in adolescents and ...

Allergic reactions come in all varieties. One can even trigger a digestive disease called Eosinophilic Esophagitis, which ...

TSLP is released in response to allergens, viruses and other airborne particles associated with asthma, COPD, CRSwNP, ...

The companies’ monoclonal antibody met co-primary endpoints in a Phase III trial in patients with chronic rhinosinusitis with ...

Regeneron Pharmaceuticals Inc. (REGN) and Sanofi have announced that the European Commission has granted approval for Dupixent ...

Dupixent approved in the EU as the first and only medicine for young children with eosinophilic esophagitisApproval based on phase 3 data showing ...

Paris: Sanofi has announced that the European Medicines Agency has approved Dupixent (dupilumab) to treat eosinophilic ...

Biotech stocks are surging as groundbreaking neuroscience and gene therapy innovations take center stage. Amid this backdrop, ...

EMA approves Dupixent to treat eosinophilic esophagitis in children as young as one year: Paris Thursday, November 7, 2024, 14:00 Hrs [IST] The European Medicines Agency has appro ...

Traditionally, this finding has been attributed solely to peptic injury, but with the advent of EoE, a second potential etiologic entity is recognized. Some patients may exhibit clinical features ...

Explore the potential of Celldex's Barzolvolimab in Phase 3 for CSU, with strong efficacy but safety concerns, promising ...

HAMPTON, N.J., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the third quarter ended September 30, 2024 and provided a corporate ...